[Circulating anticoagulants with antiprothrombinase activity in systemic lupus erythematosus (author's transl)].
Circulating anticoagulants with antiprothrombinase activity were detected in 14 out of 49 patients (i.e. 29%) presenting with severe forms of systemic lupus erythematosus (SLE) predominantly renal (29) or extrarenal (20). Nine of these 14 patients had thrombopenia and 8 had a falsely positive Wassermann test. The anticoagulants were more frequently encountered in patients with severe extrarenal manifestations (9/20 cases) than in patients with severe proliferative renal lesions (5/29 cases). They were found in 5 out of 10 patients with arterial and/or venous thrombosis. Anticoagulant levels paralleled the course of the disease during treatment. No haemorrhage was observed in 14 percutaneous renal biopsies performed on 11 patients free from outer coagulopathies. This suggests that the presence of antiprothrombinase anticoagulants in the blood of patients without thrombopenia or other coagulation disorders is compatible with surgery or biopsy of the kidney.
D001777:Blood Coagulation; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000150:complications; D008297:Male; D013925:Thromboplastin / Q000037:antagonists & inhibitors*; D013997:Time Factors; D014652:Vascular Diseases / Q000209:etiology
D013925:Thromboplastin
Anticoagulants circulants d'activité antiprothrombinase au cours du lupus érythémateux disséminé.